CATEGORY :
Anti – infective .
MECHANISM OF ACTIONS :
Vaginal Clindamycin phosphate is
hydrolyzed in vivo to Clindamycin ,
which inhibits protein synthesis in
susceptible bacteria by binding to
the 50 s subunits of bacterial
ribosomes and prevents peptide bond
formation .
PHARMACO KINETICS :
Absorption of vaginal Clindamycin :
Approximately 2% to 8% of the
administered dose ( 100 mg ) is
absorbed systemically , little or no
systemic accumulation has been
produced with multiple dosing .
INDICATIONS :
Vaginal Clindamycin is indicated in
the local treatment of bacterial
vaginosis ( previously known as
haemophilus vaginitis , gardnerella
vaginitis , non specific vaginitis ,
corynebacterum vaginitis , or
anaerobic vaginosis ) .
In addition to its use in
nonpregnant patients , vaginal
Clindamycin is indicated for use
during the second and third
trimesters of pregnancy .
Vaginal Clindamycin is not effective
in the treatment of vulvovaginitis
caused by trichomonas vaginalis ,
chlamydia trachomatis , neisseria
gonorrhoea , candida albicans , or
herpes simplex virus .
ADVERSE EFFECTS :
Cervicitis or vulvovaginal pruritus
, CNS effects ( dizziness , headache
) , gastrointestinal disturbances ,
hypersensitivity ( burning , itching
, redness , skin rash , swelling ,
or other signs of skin irritation )
not present before therapy. |
